RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties.

RHB-104's development is based on increasing evidence supporting the hypothesis that Crohn’s disease is caused by the Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients. The RHB-104 formulation was originally developed by Professor Thomas Borody, a leading innovator of therapeutic approaches to treating gastrointestinal tract diseases, who also developed the original triple therapy for peptic ulcer disease associated with H. pylori.

RHB-104 is being developed for multiple indications, including:
  • Crohn's disease - positive top-line results from a first Phase 3 study for Crohn's disease (MAP U.S. study) were announced in July 2018
  • Multiple sclerosis - a Phase 2a proof of concept study for multiple sclerosis was completed in Israel with encouraging top-line final results announced December 2016

RHB 104